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Abstract
In 2014, ARUBA (a randomized trial on cerebral Arteriovenous Malformation – 
AVM) found patients treated using prevalent interventional strategies are three 
times more likely to suffer a stroke/die compared with those treated conserva-
tively (blood pressure reduction). Subsequent controversy led the European 
societies dealing with AVM to organize a consensus conference. Among the 
statements made was: “There may be indications for treating patients with higher 
Spetzler-Martin (SM) grades, based on a case-to-case consensus decision of the 
experienced team”. Thus, a clear accord emerges. There is a lacuna/weakness of 
interventional modalities when addressing high SM grade AVMs. This lack of a 
clear treatment choice originated our review. We attempt to identify the advan-
tages and challenges of each present treatment/evaluation modality and highlight 
core requirements for future strategies. We conclude that existing modalities pro-
vide substantial recent improvements, yet the core challenge persists. Finally, we 
advocate testing a novel modality – intraluminal radiotherapy (active implants) by 
exploiting the “candy wrapper” or edge effect. If proven effective, this approach 
could offer gradual vessel occlusion with minimal abrupt hemodynamic changes 
known to induce hemorrhage, the lowest recurring session number (reduced 
costs), minimally invasive attributes and very low radiation (dose/dose rate) 
kinetics minimizing potential Adverse Radiation Effects (AREs).
Keywords: arteriovenous malformation, hemorrhage, embolization, radiosurgery, 
gamma knife, surgical resection, intraluminal radiation therapy
1. Introduction
AVM is a tangled web of blood vessels, in which arteries directly transition 
into veins without intermediate microcirculation elements that provide perfusion 
to surrounding tissue. The AVM blood vessels are called a nidus and have little 
resistance to flow compared with a normal capillary bed. Such structure manifests 
violent flows which result in increased hemorrhage risks. Due to growing use of 
advanced imaging modalities, there has been increased incidental detection of 
cerebral AVMs. When detected, there is impending need for treatment since stroke 
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chance for an unruptured and untreated AVM is ~20–40% per decade [1]. About 
38–71% of patients presenting brain AVM suffer intracranial hemorrhage [2]. Given 
these statistics, interventional treatment appears vital. Currently, three prevalent 
modalities exist: endovascular embolization, stereotactic radiosurgery (SRS), and 
surgical resection. Each modality conveys a wide risk array (safety/efficacy). Thus, 
many AVMs ultimately remain untreated (see further data below). Unfortunately, 
these are typically the larger AVMs that could better benefit from intervention 
(~76% of AVMs having a nidus <30 mm are treated; compared with ~57% of those 
having a nidus of 30–59 mm and only ~14% of those having a nidus >60 mm) [3]. 
Moreover, embolization typically necessitates a series of interventional procedures/
sessions (up to 11, on average 2.6) [4]. Each procedure involves patient hospitaliza-
tion, advanced imaging, general anesthesia, and a high-risk operation but, most 
importantly, exhibits a 3.2% chance of significant complications [4]. Finally, due 
to a low obliteration likelihood (11–40%), embolization is not recommended as a 
single-modality therapy and is usually combined with radiosurgery. Radiosurgery 
(if successful) takes 1–3 years to achieve obliteration. Thus, patients remain at 
hemorrhage risk for a lengthy treatment period [5]. To conclude, many patients 
with cerebral AVM benefit less from current prevalent treatment modalities that 
carry high risks, costs, and intensive procedures and, even if eventually effective, 
take years to complete. In 2014, the largest randomized trial on AVMs (ARUBA 
trial) found that patients treated using the prevalent interventional strategies were 
three times more likely to suffer a stroke or die compared with those treated only 
for blood pressure reduction [6]. ARUBA elicited a plethora of reactions. Some were 
relatively supportive, but many more criticized the study methods and outcomes. 
Eventually, the controversy led the European societies dealing with AVM to orga-
nize a consensus conference. A clear accord emerges. There is, indeed, a lacuna 
or at least weakness of interventional modalities when addressing high SM grade 
AVMs. The lack of clear treatment choice for a pathology with a point prevalence of 
~18/100,000 in adults responsible for 4% of all primary intracerebral hemorrhages 
is the motivation for this review [7].
1.1 Definitions and angioarchitecture
AVM features a vascular region lacking transition hierarchy, where arteries 
change directly into veins (Figure 1) [13]. AVM physical appearance is a well-
defined enclosed volume of entangled blood vessels mostly known as a “nidus.” 
Arteries entering the nidus are termed “feeding arteries” and veins leaving it are 
termed “draining veins” (Figure 2) [9].
AVMs may appear in virtually every vascular body region. Clinically, signifi-
cant AVMs are mainly classified as CNS (cerebral), pulmonary, abdominal, renal, 
Figure 1. 
AVM angioarchitecture [9].
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hepatic, and peripheral [8–16]. This chapter focuses on cerebral AVMs due to the 
high risks and challenging treatment involved with this class. Nidus sizes vary 
in diameter between 1 and 10 cm. AVMs <3 cm are classified as “small.” AVMs 
between 3 and 6 cm are classified as “medium.” AVMs >6 cm are considered as 
“large” [8]. The majority of AVMs are medium sized (~55%), followed by small 
(~38%) and then large (~7%) [17, 18]. The nidus structure does not typically 
obstruct blood flow; in fact, the opposite is true (see below). Thus, the organ 
function is usually preserved. However, in rare cases (especially large AVMs), the 
nidus is orientated or structured in a way that impedes perfusion (steal phe-
nomena) [9]. Here, clinical features of ischemia or lack of brain function may be 
present [17].
1.2 Pathophysiology
AVMs are considered as a major cause of intracerebral hemorrhage, particu-
larly in the young population (33.5% for age<20years) [19]. From a fluid mechan-
ics perspective, arterioles constitute the main flow resistance/drop of the vascular 
tree (Figure 3, OpenStax CNX) via a mechanism of rapid increase of surface 
contact between the blood and the endothelial surface and thus shear stress induc-
tion. Lack of arterioles causes minor pressure drops across the nidus. The mean 
arterial blood pressure difference between normal and AVM cases is ~40 mmHg 
Figure 2. 
AVM nidus. Physical location (left), angiogram (center), and pre-surgical anatomy (right) [9].
Figure 3. 
Pressure drop along the vascular tree.
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and has become an indicator for potential hemorrhages [20]. These findings are 
confirmed by modern 4D flow magnetic resonance imaging (MRI) and high-
resolution magnetic resonance angiography (HR 3D MRA) [21, 22]. The CNS 
vascular network is not equipped to endure pressure drops exceeding 10 mmHg, 
particularly not the structurally thin veins. Thus, the biomechanical aspects of 
AVM pressures, flows, and shear stresses play a major part in the structural failure 
of its vessels’ vascular walls.
1.3 Pathogenesis
AVM is generally considered congenital and/or of developmental origin. Beneš 
and Bradác describe several genetic pathways associated with AVM pathogenesis, 
such as hereditary hemorrhagic telangiectasia (HHT, an autosomal dominant genetic 
disease) [23]. Typically, the genes Endoglin, ALK-1 (ACVRL1, TGF-β related), and 
SMAD4 are implicated [24]. These genes also participate in angiogenesis and vas-
cular remodeling. The main signaling pathways disrupted are: (i) TGF-β—cellular 
growth, communication, and inflammatory processes; (ii) NOTCH—angiogenesis, 
considered critical for arterial fate determination; (iii) MAPK(1/3)—physiological 
and pathological cell proliferation; and (iv) PI3K/Akt—cell cycle regulation.
1.4 Epidemiology, natural history, and clinical features
Fast-flow lesions’ prevalence is estimated to be 1–2 out of 10,000 people or 
1.2–1.3 in 100,000 per person-year [23]. AVMs are found in 0.05% of all brain 
MRIs [25]. In the USA and Canada, 5000 new cases are detected yearly [26]. 
Demographic, morphological, and clinical (particularly age-related) charac-
teristics do vary, but many important pathology-related statistics (e.g., rate of 
incident hemorrhages) remain roughly similar worldwide [17]. In South Africa, 
male gender and African-black origin were found to be strong indicators for 
AVM seizure development [27]. Frontal (20.4%), parietal (22.2%), temporal 
(16.6%), and cerebellar (14.0%) are the most common anatomical brain regions 
to present AVMs [17, 27]. Supratentorial lesions account for 90% of brain 
AVMs [28]. Intracranial hemorrhage is the most common clinical presentation 
(30–82% of lesions) [29]. AVMs account for 1–2% of all strokes and 2–4% of all 
non-traumatic intracerebral hemorrhages [23]. However, the unique age distri-
bution among stroke etiologies (the median age for an AVM patient is 32 years 
old [30]) suggests that AVMs are responsible for more than a third of hemor-
rhagic strokes in young adults [19]. Furthermore, some studies suggest that 
higher hemorrhage risk values of 4.6% [31] and 30% of lesions are subarachnoid 
[32]. These are considered highly catastrophic and present the mortality rates 
of 25–50% [33]. Main factors influencing hemorrhage risk statistics are initial 
hemorrhagic (7.48%) or seizure (4.16%) presentations, associated aneurysms 
(6.93%), and deep venous drainage (5.42%) [31]. Other clinical representations 
are neurological deficits (24%), chronic headaches (19%), and focal or general-
ized seizures (46%) [17]. The American Association of Neurological Surgeons 
(AANS) provides a wide symptoms list—seizures, muscle weakness or  
paralysis, loss of coordination, difficulties carrying out organizational tasks, 
dizziness, headaches, visual disturbances, language problems, abnormal 
sensations, memory deficits, mental confusion, hallucinations, and dementia 
[34]. Annual mortality rates vary between 0.7 and 2.9% [23]. Considering an 
estimated number of 300,000 US patients, this results in ~2100–8700 annual 
mortalities in the USA alone.
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1.5 Brief history
Early AVM descriptions may date back to ~1500 BC, evidenced in the Ebers 
Papyrus description of hemorrhoids, varicose veins, and aneurysms. Vessel mal-
formations were apparently also familiar throughout the Roman and early Arabic 
empires. However, the first modern documented AVM procedure was performed 
by Hunter during the eighteenth century, the first official clinical diagnosis was 
described in 1895, and the first surgery (a feeding artery ligation) was performed 
by Giordano in 1889 and was immediately followed by a full AVM resection in Paris 
[23]. The early era of AVM microsurgery is traditionally attributed to Kunc et al. 
who suggested the whole AVM obliteration as a standalone fully efficient treatment 
strategy in 1965 [35]. The interventional radiology approach and radio-surgical 
techniques emerged during the 1980s and eventually paved the way for present 
treatment modalities. The 1980s were also pivotal regarding treatment strategies. 
Up to then, recommendations for AVM treatment were mainly institution/physi-
cian based. However, during the 1980s, Spetzler and Martin (based on vast surgical 
work) developed the first well-established AVM classification and treatment scale. 
This grading scale is considered the “gold standard” decision-making tool in the 
field to date [36].
2. Main diagnosis and imaging tools
Though AVM prevalence is estimated to reach up to 0.2% of the population, actual 
confirmed diagnosis rate is only ~0.02% [23, 37]. This significant gap is attributed to 
the fact that AVMs are congenital pathologies remaining generally mildly symptom-
atic until clinical presentation appears (unfortunately, this is typically hemorrhagic 
stroke) [23]. AVMs are mostly diagnosed and confirmed using radiology. The imaging 
findings also greatly influence treatment evaluations. Two strict AVM diagnostic cri-
teria are: indication of a nidus and clear venous drainage [38]. Angiographic elements 
evaluated as indications for AVMs’ clinical significance, and risk assessments include: 
arterial supply and venous drainage identification, nidus position, geometry, and 
size, presence of intracranial hemorrhage, and related pathologies [39]. The presence 
of aneurysms is associated with 26% of AVM patients [27].
2.1 Digital subtraction angiography
DSA is a vascular mapping technique based on conventional angiography. DSA 
involves an additional pre-processing step that removes non-vascular anatomical 
data [40]. Angiography is the gold standard methodology for the characterization 
and delineation of cerebral AVMs and in the evaluation of cerebrovascular diseases 
[41, 42]. The method dynamically displays vascular transitions and is uniquely 
able to delineate the size and number of feeding arteries and their origins, measure 
the nidus size and compactness, and evaluate venous drainage locations [42]. In 
addition to its significant diagnostic role, angiography is the main technique used 
by interventional radiologists to accurately navigate through the neurovascular 
environment and assess treatment progression and related events through inter-
ventional sessions [43, 44]. DSA is performed using selective (the catheter used for 
contrast administration is only advanced to the AVM vicinity) or super-selective 
(the catheter is further advanced to the AVM feeding arteries) approaches [23]. 
DSA is increasingly being supplanted by the less invasive computed tomography 
angiography (CTA) and the X-ray and nephrotoxic contrast-devoid MRA.
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2.2 Computed tomography
CT comprises a limited diagnostic tool for unruptured AVMs [45]. Lower density 
areas may (potentially) indicate the AVM in CT scans [46]. The great contribu-
tion of CT scanning in AVM diagnosis lies in its high sensitivity for acute bleeding 
detection, which makes it a front-end diagnostic tool when patients present acute 
symptoms related to the pathology [47]. CT is also used to assess efficacy and 
complications of embolization interventional treatments [47].
2.3 Computed tomography angiography
CTA combines the CT imaging procedure with contrast agent injection. This 
enables real-time (RT) structural presentation of neurovascular angioarchitecture 
(e.g., nidus, arterial feeders, and draining veins) and identifying associated pathol-
ogies such as fistulas and aneurysms [38]. Gupta et al. demonstrated that it is even 
possible to obtain good quality intranidal angiograms using RT CTA for anatomic 
localization of a specific catheterized (embolized) AVM region [48].
2.4 Magnetic resonance imaging
Smith et al. found MRI which is superior to CT and angiography in determining 
nidus size and location, detecting AVM effects on adjacent brain tissue, and show-
ing the obliteration extent following embolization [49]. MRI also facilitates AVM 
classification into base categories (e.g., sulcal/gyral) [23]. Use of flow turbulence 
and velocities as benchmarks has been shown to increase MRI diagnosis efficacy 
[23, 50]. MRI is considered highly efficient in detecting and delineating hemor-
rhagic episodes [23]. In addition, it can detect damage and atrophies in surrounding 
brain tissue and related pathologies such as aneurysms and fistulas. The latter are 
considered challenging for early detection and feature high annual risks for hemor-
rhagic events (7.5%) [41].
2.5 Functional MRI
fMRI is used to detect abnormalities in brain areas adjacent to AVM borders or 
deficits in specific cognitive tasks correlated with regions affected by it [41]. fMRI 
can help to evaluate AVM margins and aid in preventing damage to surrounding 
brain tissue during interventional sessions. AVMs are congenital pathologies. Thus, 
it is suggested that the developing brain neuroplasticity will present different fMRI 
images for healthy and pathologic cases. Caramia et al. used fMRI and transcranial 
magnetic stimulation (TMS)—which directly explore cortical neurons’ electrical 
activity—and showed cortical motor areas reorganized in the AVM containing 
hemisphere [51]. The main limitation of fMRI is that it does not directly detect 
AVMs as MRI does. Therefore, it should be used as a treatment planning tool rather 
than for standard diagnostics [23].
2.6 Magnetic resonance angiography
MRA is valuable in providing AVMs with 3D angiographic images and hemody-
namic data [23]. MRA techniques are characterized by two main parameters—flow 
and contrast. State-of-the-art MRA techniques are:
• Time-of-flight (TOF) MRA: TOF-MRA or inflow angiography enhances blood 
flow areas by shortening the MRI echo time (TE) parameter, thus reducing the 
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execution number in each flow-related voxel in comparison with stationary 
voxels. This results in flow patterns appearing brighter. The technique can also 
aid in finding residual AVMs [41]. However, Lee et al. report the accuracy and 
specificity rates of only 75–78 and 68% respectively, which leaves DSA at the 
front-end [52].
• Phase contrast (PC) MRA (Figure 4): In PC-MRA, phase shift differences 
between stationary tissue and flowing blood results from the application of 
a bipolar phase-encoding gradient and a velocity-encoding factor [23]. Since 
phase change is coupled with velocity vectors, the technique is considered 
superior to TOF-MRA (better detecting flow directions, minor velocity 
changes, and slow regions). Chang et al. used PC-MRA post-processing 
computational fluid dynamics to calculate shear stresses at vascular walls [22]. 
Wu et al. used PC-MRA to identify peak flows, velocities, and their exact loca-
tion within the nidus and feeders [53]. To conclude, PC-MRA is a promising 
technology but is still not comparable with conventional angiography [23].
• Time-resolved imaging of contrast kinetics (TRICKS) MRA: Here, continuous 
imaging is employed during the passage of a contrast agent yielding a movie 
with an acquisition rate of up to three frames per second [41]. These improve-
ments enable the visualization and calculation of flow through regions of 
the AVM (also selectively), enabling confirmation of suspected findings on 
conventional imaging tools [41]. The technique findings correlate well with 
DSA with regard to nidus size and location, venous drainage pattern, and 
arterial feeders in multiple studies but still lag DSA in spatial and temporal 
resolutions.
2.7 Diffusion-weighted MRI
These methods are based on the diffusive anisotropy of water molecules along 
nerve axons and plexus, where axial motion takes precedence [41, 54]. Here, we 
can find techniques such as diffusion tensor imaging (DTI), diffusion spectrum 
imaging (DSI), and high angular resolution diffusion imaging (HARDI). These 
more recent techniques serve as a valuable non-invasive pre-operative and pre-
radiosurgery tool to evaluate the involvement and proximity of cerebral AVMs to 
white matter tracts [41]. Using these methods, it provides clinicians with strong 
risk assessment capabilities, particularly regarding the microsurgery approach and 
track planning [55]. dwMRI can be used with other technologies for presenting a 
combined vascular and neuroanatomical image [55]. It might also enable very early 
identification of ischemic areas [46]. dwMRI is limited mainly to white matter 
tracts and presents high sensitivity to protocol operation parameters (e.g., TR/TE/
spatial resolution) and artifacts from inadvertent sources.
Figure 4. 
(A) PC-MRA original image of right temporal AVM, with (B) velocity, (C) whole brain, and (D) feeding 
arteries shear stresses data [22].
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2.8 Summary
AVM analysis is based on the findings of multiple modalities—vascular anatomy 
of nidus and feeders, acute/chronic brain matter pathological presentations, flow 
and velocity rates, and surrounding tissue anatomical and functional attributes 
(e.g., connectometractography). Each modality presents specific strengths and 
weaknesses. CT is extremely sensitive to hematomas and offers several AVM 
anatomical finding capabilities. CTA is used to diagnose AVM in patients with acute 
hematomas. MRI presents improved topography and the detection of subacute and 
chronic hematomas and surrounding brain tissue pathologies. PC-MRA is used 
for high-resolution vascular imaging and provides biomechanical data (e.g., shear 
stresses), that is, highly beneficial in clinical assessment. Functional-anatomical 
relations data are effectively gathered using fMRI and dwMRI which provide strong 
clinical decision-making tools. Finally, DSA remains the gold standard for both 
diagnostic and procedural purposes due to its high-resolution real-time imaging of 
cerebral angioarchitecture. To conclude, brain imaging is a prolific field constantly 
presenting the development of promising improved and new modalities.
3. Grading and classification
3.1 The SM grading system
In 1986, Spetzler and Martin published a relatively simple AVM classification 
system called “SM Grading” [36]. SM is considered as the gold standard to date. 
The system requires three parameters, evaluated using angiography, CT, and MRI 
(Table 1): size, venous drainage pattern (“superficial” if all drainage is via corti-
cal veins and “deep” if some or all drainage is via deep veins), and neurological 
eloquence of adjacent brain regions (“eloquent” regions are those well-defined 
by a neurological function, while the regions of less defined function or disabling 
effects when disrupted such as temporal lobes and cerebellar cortex are considered 
“non-eloquent”). SM eventually sorts AVMs into five grades. Inoperable AVMs are 
considered grade six. Spetzler and Martin correlated their grading with the surgical 
outcomes of 100 patients and found it to be well-correlated with both minor and 
major post-operative neurological deficits. Further validations were later performed 
by both the authors and peers [56].
3.2 Modifications of SM
Several modifications of the SM grading system have been suggested over the 
years. Following are some key examples. De Olivera et al. suggested including 
Graded 
feature
AVM size (cm) Eloquence of adjacent 
brain
Pattern of venous 
drainage
Small 
(<3)
Medium 
(3–6)
Large 
(>6)
Non-
eloquent
Eloquent Superficial Deep
Points 
assigned
1 2 3 0 1 0 1
Grade = [size] + [eloquence] + [venous drainage]; that is (1, 2, or 3) + (0 or 1) + (0 or 1).
Table 1. 
Determination of AVM grade [36].
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two Grade 3 subgroups with different patient management [57]: 3a (large size, 
pre-operative endovascular embolization followed by microsurgical resection) 
and 3b (venous drainage and/or eloquence, generally treated with radiosurgery). 
They found their modified classification a useful guide for the best treatment but 
indicated that it has many exceptions. Lawton et al. suggested further subcatego-
rizing Grade 3 AVMs into four classes for better correlating the SM grading with 
associated surgical risks (− less risk, + more risk) [58]: Grade 3−AVMs (small nidus 
size, deep venous drainage, and eloquent adjacent brain tissue) have a surgical risk 
similar to that of low grade AVMs and can be safely treated with microsurgical 
resection, Grade 3+ AVMs (medium size, superficial drainage, and eloquent) have 
a surgical risk similar to that of high-grade AVMs and are best managed conser-
vatively. Grade 3 AVMs (medium, deep, and non-eloquent) have intermediate 
surgical risks and require judicious selection for surgery. Grade 3* AVMs (large, 
superficial, and non-eloquent) are either exceedingly rare, with a surgical risk that 
is unclear, or theoretical lesions with no clinical relevance. Finally, fairly recently in 
2016, Neidert et al. suggested a grading system for patients with ruptured AVM-
related IntraCerebral Hemorrhage (AVICH) to predict clinical outcome [59]. Their 
system extended SM with parameters such as age, diffuse nidus (from the Lawton-
Young grading system, that added patient age, hemorrhagic presentation, nidal 
diffuseness, and deep perforating artery supply in 2010 to improve neurological 
outcome prediction and refine patient selection [60]), intracerebral hemorrhage 
volume (30 CC threshold), and intraventricular hemorrhage (derived from the 
intracerebral hemorrhage score). They demonstrated that their score predicts the 
outcome of patients with ruptured AVM and associated ICH better than previ-
ous grading systems (SM included). They cautioned that an external validation is 
needed before this score is tested in a prospective multicenter cohort. To date, no 
modified grading system has become as well-established as the SM grading.
3.3 SRS grading scales
Schwartz et al. tried to predict the AVM obliteration success of single-dose 
photon SRS for individual patients [61]. They defined the obliteration prediction 
index (OPI ≡ marginal dose of radiation given at the edge of the target lesion in 
gray/lesion diameter in centimeters). They concluded that the exponential func-
tion  P = 1 − A  e −B⋅OPI (where  P is the obliteration probability and  A, B are constants) 
is well-correlated with successive chance, partly describes the biological effect of 
radiation, and is independent of the device (marginal dose) used. They suggested 
that radiosurgery centers use this model to facilitate successful treatment prediction.
Pollock-Flickinger developed a grading system to predict excellent patient out-
come (complete AVM obliteration without any new neurological deficit) following 
single session AVM radiosurgery [62]:
 AVM score  =  0.1  AVM volume [ cm 
3 ] + 0.02 Patient age  [years]  
+ 0.3  AVM location 
∗
  (1)
where * indicates: frontal or temporal = 0; parietal, occipital, intraventricular, 
corpus callosum, or cerebellar = 1; basal ganglia, thalamic, or brainstem = 2.
They concluded that their proposed AVM grading system strongly correlates 
(R2 = 0.88) with patient outcomes but cautioned that further testing by indepen-
dent centers using prospective methodology is still required.
In 2016, Pollock et al. compared five AVM grading scales—SM, radiosurgery-
based AVM score (RBAS), Heidelberg score, Virginia Radiosurgery AVM Scale 
(VRAS), and proton radiosurgery AVM scale (PRAS)—at predicting SRS outcomes 
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Grading scale and year Variables Type of scale (range)
Size Vol Patient age (years) Location Venous drainage Presentation
SM, 1986 6 cm = III NA NA Non-eloquent = 0
eloquent = 1*
No = 0
yes = 1
NA Integer-based
(1–5)
Modified RBAS, 2008 NA 0.1× vol in ml 0.02×age 0.5× (not deep = 0, deep = 1)† NA NA Continuous
HS, 2012 <3 cm
or
≥3 cm
NA ≤50
or
>50
NA NA NA Integer-based
(1–3)‡
VRAS, 2013 NA 4 cm3 = 2 NA Non-eloquent = 0;
eloquent = 1*
NA No bleed = 0
bleed = 1
Integer-based
(0–4)
PRAS, 2014 NA 0.26× vol in ml NA 0.7× (not deep = 0, deep = 1)† NA NA Continuous
HS, Heidelberg score; NA, not applicable.*Eloquent location is defined as sensorimotor, language, or visual cortex, hypothalamus, thalamus, brain stem, cerebellar nuclei, or regions directly adjacent to these 
structures.
†Deep location is defined as basal ganglia, thalamus, or brainstem.
‡Heidelberg score: 1 = (<3 cm and ≤ 50 years), 2 = (either <3 cm or ≤50 years), and 3 = (≥3 cm and>50 years).
Table 2. 
AVM grading scales [63].
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(Table 2) [63]. Their criterion was AVM obliteration without a decline in modified 
Rankin Scale (mRS) score (excellent outcome). They concluded that continuous 
scores AVM grading scales (RBAS and PRAS) outperformed integer-based grading 
systems in the prediction of AVM obliteration outcomes since they directly correlate 
with patients’ existing physical attributes.
3.4 Grading systems for embolization
Even though endovascular embolization widely differs from surgical or SRS 
approaches, dedicated grading was not considered as a broad/general tool until 
fairly recently. In 2010, Feliciano et al. conducted an extensive literature survey 
and correlated endovascular treatment with AVM characteristics. Points were given 
according to feeding vessels, eloquence, and fistulae presence (Table 3) [64]. They 
concluded that a grading scale similar to SM for use in risk assessment and outcome 
determination in brain AVM patients treated by endovascular techniques seems 
adequate and clinically feasible.
3.5 Summary
Though posited in 1986, the SM AVM grading system remains the gold standard 
in predicting surgical treatment success. The development and assimilation of SRS 
led to uniquely dedicated grading. The future probably lies with “continuous” grad-
ing, where scores are directly correlated with AVM and patients’ actual features and 
properties. Endovascular dedicated grading has just recently emerged, mostly based 
on large literature surveys and meta-analyses, but apparently shows real promise 
(though it still necessitates firmer actual validation).
4. Embolization
Embolization is intended to physically block blood flow to the AVM. It is a mini-
mally invasive endovascular procedure carried out by an interventional radiologist. 
AVM embolization is considered among the most challenging in the field due to 
the vasculature target tortuous hemodynamic formation but, more so, due to its 
high-pressure arteries directly connecting with low-pressure veins (AV shunts). If 
arteries are proximally occluded, anastomoses develop from nearby vessels creat-
ing new shunts. Thus, proximal arterial occlusion has no curative effect and is 
restricted to pre-surgical situations [23]. In contrast, direct AVM treatment requires 
AVM feature Points
Number of feeding vessels <3 1
3–5 2
≥6 3
Eloquence of adjacent areas Non-eloquent 0
Eloquent 1
Presence of AVFa No AVF 0
AVF 1
aAVF = arteriovenous fistula or fistulous component.
Table 3. 
Classification scheme for risk assessment during embolization procedures for brain AVMs [64].
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distal (transarterial) embolization. First, navigation is performed all the way to 
the venous section. Then, an embolic agent is super-selectively introduced into the 
draining veins via microcatheters that are retracted backwards as the vasculature 
fills up (all the way to the arterial feeders). Vessel selection tract is traditionally 
based on DSA.
In 1995, Frizzel et al. reviewed the cure, morbidity, and mortality associated 
with the embolization of 1246 brain AVMs during the previous 35 years [65]. Cure 
rates were 4–5%. Temporary and permanent morbidities were 10 and 8–9%, respec-
tively. Mortality was 1–2%. These statistics improved over the years. However, to 
date, embolization is generally considered a pre-operative (pre-SRS) adjunctive 
procedure because: (I) as a sole modality, it is assumed effective only in a minority 
of cases [66]; (II) proximal occlusion of feeding arteries appears to be associated 
with recurrence [66]; and (III) it appears to increase hemorrhagic risk compared 
with conservative management, especially in unruptured AVMs [67].
Currently, the two most common embolization agents in cerebral AVM treat-
ment are N-butyl cyanoacrylate (NBCA) and ethyl-vinyl alcohol copolymer 
(EVOH)-DMSO solvent (Onyx) [68, 69]. These materials are delivered in liquid 
form and are, hence, injectable through very narrow diameter microcatheters.
4.1 Cyanoacrylates
Cyanoacrylates solidify by polymerization initiated once they contact an anionic 
environment such as blood [69]. The process is very rapid but can be delayed by 
dilution using Lipiodol (Ethiodol in the USA) vehicle retardant. The more Lipiodol 
the mixture contains, the longer the delay. Optimizing dilution is a very empirical 
process that greatly depends on operator experience level. Cyanoacrylates’ main 
advantages are that they: facilitate nearly instant occlusion; induce an inflammatory 
response within the embolized vessel walls that are believed to play an important 
role in the occlusion durability; are compatible in case of vascular rupture; are 
injectable via many microcatheter types (even the thinnest and most flexible ones 
currently available); have a non-glued microcatheter withdrawal that gives rise 
to minimal vascular network traction, so they are highly compatible with narrow 
diameter arterial vessels (very sensitive to traction-induced mechanical trauma); 
and facilitate surgical resection by helping to identify embolized vessels (compress-
ible and easily cut with micro-scissors). Cyanoacrylates’ main drawbacks are: 
catheter can become entrapped in the occluded vessel; difficulty in controlling the 
occlusion position; highly local occlusion; they can only be used by operators with 
extensive training; must be opacified to monitor flow during injection; and catheter 
position must be abandoned.
4.2 EVOH copolymer-DMSO solvent (Onyx)
Here, small polymer particles are suspended in solution using a DMSO solvent 
[69, 70]. Following mixture injection, DMSO diffuses to surrounding tissue, 
resulting in particle aggregation occluding the lumen. Flow is omnidirectional and 
typically includes artery reflux along the microcatheter tip. Following injections 
progressively colonize adjacent arteries, only then traveling towards the drain-
ing veins. Consequently, microcatheter tip trapping is a typical feature. This led 
manufacturers to develop catheters with detachable tips. Onyx’s main advantages 
are: relatively high complete obliteration rate with the evidence of stability over 
time [70]; slow solidification facilitates prolonged/controlled injection with deeper 
nidus penetration; and mid-procedure angiography and reduced catheter adherence 
even during reflux. Onyx’s main drawbacks are: DMSO is toxic—rapid injection can 
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cause vasospasm, necrosis, and acute respiratory distress syndrome (ARDS) [71]; 
DMSO-compatible catheters and syringes must be used; high radiopacity causes 
poor visualization during reflux in very small vessels and masking by previously 
embolized regions potentially leading to subsequent healthy vasculature emboliza-
tion; over-reflux can potentially harm adjacent functional healthy arteries; and 
mixture must be shaken for at least 20 min prior to usage in order to homogenize 
the tantalum powder used for opacity.
4.3 Precipitating hydrophobic injectable liquid
PHIL is a recent liquid agent composed of a non-adhesive copolymer 
(polylactide-co-glycolide and polyhydroxyethylmethacrylate) dissolved in 
DMSO. Triiodophenol is used as an iodine component, being covalently bound to 
the copolymer for radiopacity [72]. Initial studies show embolization characteristics, 
embolization extent, and biocompatibility to be comparable with those of Onyx 
[72–74]. However, further studies are required to fully evaluate its safety and efficacy 
[74]. PHIL main advantages are: shorter pause times that result in significantly 
higher embolization success compared with Onyx; lower volumes required for the 
same extent of embolization compared with Onyx; it comes ready for use (does not 
require preliminary preparation); and improved visibility compared with Onyx. 
PHIL’s main drawbacks are: still necessitates DMSO; embolization performance (effi-
cacy) is only comparable with that of Onyx but does not improve on it; and could 
result in the exertion of traction on the vascular network upon catheter extraction.
4.4 AVM embolization complications
Post-embolization hemorrhage is the most severe, dramatic, and morbidity-
mortality-related complication [75]. Up to 14% of patients exhibit neurological 
deficits [75, 76]. The combined death and permanent disabling neurological deficit 
rate is below 3.9% per patient [77, 78]. Risk predictors for endovascular treatment 
differ from those for AVM surgery [76]. Some studies report no morphological 
AVM characteristics test predict treatment complications [76]. Others suggest AVM 
location in an eloquent brain part, and fistula presence and a venous glue deposi-
tion are associated with complications [77]. Yet, others consider that basal ganglia 
location is weakly associated with new post-embolization neurologic deficits [78]. 
This topic is controversial. It appears that extensive devascularization and the 
absence of post-procedure hypotension increase hemorrhage risk [75]. Thus, partial 
(25–30%) devascularization per session and post-procedure hypotension induction 
were recommended [75]. Overall, there is a consensus that brain AVMs’ emboliza-
tion is associated with low overall mortality and disabling morbidity rates [77, 78]. 
The hemorrhage mechanisms are typically: artery perforation by a microguide/
microcatheter during navigation; excessive pulling on a stuck microcatheter; and 
hemodynamics-related rupture due to changes in flow patterns and commination 
(size reduction) in venous drainage. These are typically the most severe and occur 
within 48 h following embolization. Finally, thrombus formation and its migration 
from the carrier catheter leading to ischemic complications is a feasible though 
non-frequent scenario.
Embolization complications dictate clear design recommendations for future 
endovascular devices: gradual blood vessel closure in which no abrupt flow changes 
take place inside the nidus; the ability to treat small and big blood vessels, easier 
to operate when treating patients—requiring reasonable training and experience 
(and skills); and avoiding exerting significant mechanical stresses on the delicate 
vasculature.
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5. Stereotactic radiosurgery
SRS is a leading alternative to surgery or embolization, especially for AVMs 
located in deep or eloquent brain regions, where invasive treatment is not optional 
[79]. SRS employs ionizing radiation for gradually occluding AVM blood vessels. 
Its application was adopted from oncology during 1970–1980s [80, 81]. During the 
next decades, SRS (or “gamma-knife”) rapidly evolved as a standalone modality 
and following embolization. SRS systems typically comprise a spherical array of 
high-focused gamma ray generators (Figure 5), a mechanical system that precisely 
positions and immobilizes patients’ heads and a 3D imaging, and tracking system 
for treatment (i.e., dose delivery) design and real-time management (Figure 6). 
The chief benefit of radiosurgery is that it can eliminate the threat of spontaneous 
intracranial hemorrhage by gradual obliteration of the AVM over 2–3 years [81].
5.1 Histopathological response
Radiation induces endothelial damage (lasting biochemical changes and apoptosis), 
thrombocyte aggregation/development of fibrin microthrombi, and subendothelial/
perivascular spindle cell proliferation (contractile myofibroblasts formed in vascular 
walls and AVM connective tissue—stroma) [23, 82, 83]. Both degenerative and 
proliferative changes are dose- and time-dependent. Degeneration expressions are 
tissue granulation and inflammatory cell presence in the stroma followed by type IV 
collagen-producing fibroblasts and fibrocytes and eventually hyaline phenotypics 
and obliterated vessels. Proliferation is expressed by the formation and accumulation 
of myofibroblasts (neointima) assumed as the canonical shrinking and occlusion 
factor in irradiated AVMs [23, 82, 83]. Importantly, normal vessels do not exhibit 
propensity to obliterate. Apparently, due to the connective tissue (stroma) surround-
ing the AVM nidus, pathological vessels playing a key role in the obliteration process 
[23, 84]. Obliteration is often followed by new vessel formation, occasionally visible 
on MRI [23, 82]. Radiation-induced necrosis, neural loss, myelin fragmentation, and 
gliosis have been detected in the surrounding brain tissue 1–10 mm from the lesion 
Figure 5. 
Schematic illustration of a stereotactic radiosurgery procedure [© Mayo clinic].
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border [23]. Histopathology is typically elicited and efficacy-controlled by focused 
irradiation of marginal doses of ~10–35 Gy (median ~20) (Figure 6)—delivered in a 
single or fractionated (higher doses) protocol [81, 82]. It has become a consensus that a 
better understanding of irradiation response physiology may facilitate the targeting of 
individual enzyme systems and open up new SRS opportunities [84].
5.2 Widely used systems
Gamma-knife systems consist of up to ~200 cobalt-60 sources arranged in 
circular arrays within a spherical mechanism [79]. The arrays’ geometry and source 
strength (typically ~30 curies each) result in a 3D energy field of isodoses at any 
defined volume within the sphere. While each source beam dose is very low, the 
converged irradiation at any pre-chosen focus position adds up to clinical values. 
The targeted volume can be varied using different sized collimators. These systems 
Figure 6. 
Top: SRS treatment planning (dosimetry). Using imaging scans and specialized software, the treatment team 
determines the best combination of radiation beams to target the lesion [© Mayo clinic]. Bottom: marginal 
dose versus efficacy (following [81]).
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traditionally required complete patient immobilization—which involves direct 
mechanical fixation of patients’ skulls using a stereotactic frame. The fixation is 
an invasive procedure that can be highly painful and stressful. Newer models can 
perform frameless treatment (thermoplastic mask for immobilization and advanced 
imaging for stereotactic orientation), thus supporting a less invasive patient experi-
ence. Gantry and robotic arms systems employ gantry-mounted linear accelera-
tors (“LINACS”) to generate the energy beam and rely on either fixed circular or 
multi-leaf collimators (MLCs) for its shaping. This allows a conformal scheme—
which aids in treating irregular nidus geometries. Alternatively, the system can be 
mounted on a robotic platform (arm vs. gantry) that adds mechanical degrees of 
freedom. Patient positioning can also be achieved using imaging (cone beam CT) or 
laser systems, so frame-based immobilization systems are becoming obsolete. Less 
common are proton beam systems that accelerate protons (using a synchrotron or 
cyclotron) in order to generate the therapeutic beam. An advantage of proton treat-
ment is the minimal target-exiting dose safeguarding the lesion surrounding tissue. 
The proton beam is typically delivered to the target volume via a gantry mechanism. 
Patient immobilization can be achieved invasively and non-invasively. Proton 
systems’ main disadvantage is that they are scarce and expensive.
5.3 Treatment selection
Since radiosurgery/therapy equipment is scarce and extremely expensive, 
many centers and physicians have adopted particular patient selection and treat-
ment protocols. The availability of different systems per hospital/clinic has further 
contributed to this diversity. The result has been that there are many controversies 
regarding patient and modality selection in general, and with respect to radiosur-
gery/therapy in particular [85]. During the last two decades, this trend has been 
changing as more physicians and researchers are attempting to standardize score-
based radiotherapy grading and patient selection systems (see Section 4.3) [59]. 
A treatment selection scheme established at Pittsburgh University is presented in 
Figure 7 [81]. Selection relies on AVM volume and location as well as the existence 
of post-treatment (residual) lesions.
Unlike SM grading in surgery, to date, there has been no distinct established 
treatment selection criterion for radiosurgery/therapy. Even recent advanced grad-
ing systems are not widely considered a sufficiently standardized basis for designat-
ing a patient for radiation modality. Common factors are bleeding history, patient 
age, existing comorbidities, anatomical location, and clinical history [81].
5.4 Outcomes and complications
Standard protocol for AVM obliteration typically involves clinical diagnostics 
and a half-yearly MRI, followed by annual MRI imaging. Final validation (classi-
cally at 3 years) is DSA-based, as the latter constitutes the gold standard [81]. A 
meta-analysis, performed by Badra et al. in 2018 [79], found that: obliteration rates 
are ~70–80% at 2–4 years post-treatment; annual bleeding rates are 1.1–8%; AREs 
are 12–38%; and overall morbidity is 4–12%. Another study showed [81]: the oblit-
eration rates of 78% at 3-year follow-up, repeated radiosurgery needed in 12.5% of 
cases, post-surgery annual bleeding rates in 4.1% of cases, and AREs in 16.3%. Thus, 
while radiation treatment is relatively effective, it is not risk- and complication-free. 
Several categories merit particular attention: acute complications are typically 
related to the post-procedural presentation of neurological deficits after 2 years or 
more. Yen et al. studied 1426 Gamma Knife Surgeries (GKS) and found radiation-
induced imaging changes (RICs, visualized as increased T2 signal surrounding the 
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treated nidi on MRI) that are the most common adverse effects following GKS—in 
33.8% of lesions [86]. Patients with a relatively healthy brain and large nidi or with 
a single draining vein were more susceptible to RICs. Few RICs were symptomatic 
(8.6%), and most symptoms were reversible (only 1.8% had permanent deficit). 
About 7.7% of RICs were acute—causing a midline shift of the brain. Late AREs 
typically occur many years following SRS (6.9% of patients after a median of 
8.7 years. The 5-, 10-, and 15-year incidence is 0.4, 7.7, and 12.5%, respectively). 
They are characterized by perilesional edema or cyst formation and are distinct 
from short-term (1–2 years post-surgery) AREs, often labeled as RICs [87]. About 
3.4% of Late AREs are symptomatic at detection. Many that are asymptomatic later 
present with cyst progression. The overall symptomatic rate of late AREs is 4.7% 
[87]. Another study included radiation necrosis and cystic vessel formations in late 
ARE diagnosis and found the incidence at 2–6% [79]. Finally, since radiotherapy 
for AVM is based on ionizing radiation, the concern for carcinogenicity arises. 
However, little evidence has been found to support radiation induced tumors 
(RITs). A late retrospective analysis performed by Pollock et al. found no RITs in 
471 patients observed between 1990 and 2009 (with very few others out of the total 
1837 patients presenting malignant transformation) [88]. The authors concluded 
that the risk of RITs or malignant transformation after SRS is very low and should 
not be used as a justification for choosing alternative treatments. Lunsford et al. 
corroborate these findings [81].
5.5 Fractionated radiation/treatment
FR strategy is intended for treating large lesions that carry increased mortality 
and morbidity using interventional methods and lower obliteration rates or longer 
obliteration time when treated using radiotherapy. Unfortunately, large AVM is 
not a well-defined or accepted criterion in the literature. SM refer to >6 cm along 
the nidus largest diameter. Other studies define a volumetric condition >10 (cm3) 
[62]. However, there is a consensus that high single-fraction doses as used in small 
AVMs increase radiation injury risks and associated neurological deficits when 
Figure 7. 
AVM treatment selection scheme (following [81]).
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large normal brain volume is exposed to high doses [89]. Two approaches exist to 
improve safety and efficacy in these cases: (1) fractionation radiosurgery (FR) 
where total dose is equally divided into fractions delivered over multiple sessions 
(days scale), so brain tissue adjacent to the lesion can tolerate higher integral doses. 
(2) Volume staged radiosurgery where the AVM is typically divided into 2–4 
spatial regions each treated separately using a high single-fraction dose. Between 
treatments, a rest period (3–9 months) is imposed. Here, each AVM part is instantly 
treated with a clinically effective dose. Normal brain tissue recovers between treat-
ments. This makes it possible to tackle the main disadvantage of FR—low fractional 
doses are relatively less effective at treating AVM and result in reduced obliteration 
rates unless the total dose is substantially increased [89]. However, a main concern 
of this approach is that partial AVM obliteration apparently alters blood flow 
patterns and increases hemorrhage risks [89]. Currently, there is a little evidence 
for the superiority of one approach over the other [89]. In general, it is highly 
recommended to minimize the integral dose to the normal brain of asymptomatic 
patients. Recently, Unkelbach et al. elegantly demonstrated that by boosting 
complementary parts of the target volume in different fractions, it may be possible 
to achieve a therapeutic advantage in FR since this approach facilitates mean dose 
reduction in the normal brain [89]. To date, FR has not been widely accepted as 
presenting a compelling advantage over multi-modality treatments such as initial 
size reduction using embolization.
5.6 Summary
While gaining popularity and presenting impressive treatment success rates of 
~80%, radiosurgery still has distinct limitations that must be faced. Obliteration 
typically takes 2–3 years during which patients remain exposed to significant annual 
bleeding risks of 4–5% (twice that of conventional treatment) and overall morbid-
ity rates reaching 12%. Large (SM grade ≥ 3) AVMs necessitate multi-modality 
or fractionated treatment. The latter shows promise but requires further study if 
efficient management is desired.
6. Surgical resection
6.1 Patient selection and outcome predictors
The SM grading system for predicting patient outcome is microsurgery-based 
and remains the gold standard in the field [36]. Though the physiological origins 
of each AVM’s clinical presentation are unknown, SM and supplemental grading 
systems have been validated on numerous occasions (see above). These systems 
apply to both patient selection and outcome prediction. Recently, Kim et al. demon-
strated, in a cohort study performed on 1009 AVM patients at four institutions, that 
supplemented SM grades (SM-Supp, also considering the patient age, bleeding his-
tory, and compact anatomy indication) have greater predictive accuracy than stand-
alone SM grades [90]. Their findings are not unique in that they show improvement 
over SM. They also rightfully conclude that “current grading systems are imperfect 
and evolving and that as the pathophysiology, hemodynamics, and genetics of 
AVMs are elucidated through research, grading systems will incorporate these 
advances.” We, however, believe that there is a great difference between academic 
and clinical settings. We acknowledge that complex grading schemes may present 
improved predictability and selection capability. However, we believe practitioners 
must be provided with simple, intuitive, and relatively easy-to-use schemes. Only 
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such schemes will be readily accepted and rapidly/easily implemented in clinical 
settings, particularly in emergency cases. We, therefore, recommend that the fac-
tors incorporated into future grading schemes remain relatively accessible (direct) 
and limited in number.
6.2 Standard microsurgery protocol
We briefly (and humbly) review key steps involved with AVM microsurgery 
[23, 37]. Once a patient is designated for microsurgery, treatment planning and 
evaluation begins. Often, additional imaging is performed to provide maximal 
data for a solid operating plan. Here, 3D reconstruction can prove very helpful and 
emphasis should be given to study the AVM main feeders. Pre-operative steps 
include patient positioning (one that provides a good venous return and preferably 
has the AVM surface aspect horizontal at the top of the approach and the longest 
axis of the nidus vertical) and craniotomy (removal of part of the skull to expose 
the brain), which provides exposure to the lesion area. Here, caution must be 
exerted to ensure the craniotomy is larger than the AVM surface while safeguard-
ing the delicate dilated and exposed draining veins during dura opening (against 
adhesion). Only then can AVM resection be performed. The procedure in general 
is directed from the arterial towards the venous side of the nidus. All vessels must 
be coagulated or clipped. It is customary to leave true feeders to the end since their 
earlier occlusion can lead to the recruitment of blood flow from deep feeders and 
may cause their rupture [23]. It is important to ensure that draining veins present 
no evident flow. Eventually, the nidus is gently rolled out of the resection cavity. 
Post-operative management includes admitting the patient (while completely 
sedated) to the Intensive Care Unit for close observation for evidence of post-
operative bleeding or swelling. A post-operative CT is typically performed shortly 
after the procedure to rule out any such complication followed by a mandatory 
angiography performed on day 2–3 after surgery.
6.3 Results and complications
The main advantage of AVM microsurgery is its “straightforward” approach, which 
allows relatively definite lesion resection and rapid clear follow-up. Microsurgery is 
considered the gold standard in AVM obliteration. It presents a high success (cure) 
rate reaching 99% in small SM 1–2 grades [91–93]. Treatment challenges include 
limitations regarding accessibility (deep locations) and a high risk of severe complica-
tions that contribute to the mortality and permanent morbidity rates of 3.3 and 8.6%, 
respectively, as seen in a meta-analysis performed in 2425 patients between 1990 and 
2000 [8]. A more recent study found permanent mortality and morbidity rates of 1.7 
and 4.8% (2.2% permanent significant morbidity) [91], and yet, another study found 
the permanent mortality and morbidity rates of 7.9 and 14.8% (though obliteration 
rate was 87.2%) [92]. Additional studies present early and permanent disabling deficits 
in 12.3 and 4.5%, respectively, permanent neurological deficit in 16.1% [93], periop-
erative neurological deficits of 17%, annual hemorrhage rate of 0.3%, and a recurrence 
rate of 0.9% in children [94]. These findings and others clearly demonstrate the 
pronounced variations in the modality outcomes depending on surgeons’ expertise, 
patients’ AVM grading distribution (e.g., 7% neurological deficits at SM Grade 1 
compared with 50% at SM 5 in [90]), prior bleeding presentations, multi-modality 
protocol (e.g., surgery following embolization or radiosurgery as in [95]), and so 
forth. A review of the literature indicates that the leading risks of surgical resection 
are intraoperative rupture, post-operative hemorrhage, and post-operative edema. 
These hemodynamic events can become life threatening and disabling. Additional 
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complications of reduced risk are neurologic deficits from over-dissection or ischemia, 
seizures, hydrocephalus, and infections [23, 37]. The subject of lesion recurrence 
following microsurgery has been controversial. Different centers report highly varied 
outcomes. Recently, Aboukaïs et al. analyzed the subject and reported the recurrence 
as a fairly rare case (7/138 cases) affecting mostly pediatric patients. They recommend 
particularly long-term angiographic follow-up in children to detect AVM recurrence or 
remnants [96].
6.4 Emerging trends
Brain microsurgery is a proliferating field presenting many interesting develop-
ments in imaging, treatment management, surgical approach, and so forth. We very 
briefly mention a few promising directions. Molecular imaging employs specific 
antibodies combined with detectable agents such as gadolinium [55]. This tech-
nique was used to image particular receptors on tumors and could non-invasively 
detect biological markers in AVM vessels. If an appropriate biomarker imaging 
probe for AVM is discovered, it will facilitate highly selective lesion diagnosis and 
analysis. Specific conditional biomarkers (activated by physiological occupancy 
of enzymes, ions, and metabolites) can possibly even support super-selective 
procedures. Rad et al. demonstrated that vessels within the mature rat AVM exhibit 
elevated phosphatidylserine (PS) externalization compared with normal vessels 
[97]. Ionizing radiation increased PS externalization in a time-dependent manner. 
They concluded that the AVM localization of PS externalization may function as 
a tool in future SRS treatment. Image guidance provides a promising technique, 
particularly when incorporated into patient intraoperative 3D viewing and simulat-
ing systems [98]. It facilitates improved AVM localization, clearer venous anatomy, 
better definition of craniotomy, and so forth for the surgeons, and may reduce 
intraoperative risks. Spetzler and Sanai used dynamic retraction (retractorless 
surgery) and a variety of advanced handheld instruments with considerable success 
and suggest that fixed retraction can be supplanted by this approach, thus limiting 
the risk of retractor-induced tissue edema and injury [99]. There are additional 
promising directions outside the scope of this chapter. However, most of those 
mentioned (as well as those not discussed here) still lack a large enough database 
for establishing clinical superiority.
6.5 Summary
The neurosurgical aspect of AVM treatment presents a versatile picture. While 
SM Grade 1–2 lesions are treated with good efficacy and low risks (as well as a few 
Grade 3 cases), successful outcome rapidly declines in medium-to-large lesions, 
demonstrating high risk for adverse outcomes (transient and permanent neurological 
deficits as well as mortality). These high risks do not markedly decline when address-
ing large AVMs using a multi-modality approach. Perhaps because such procedures 
are not yet sufficiently established, we cannot currently provide this statement with 
distinct supporting evidence. Small AVMs constitute a large portion (~40% or so 
based on our literature observations) of all lesions. This leaves many cases without 
direct surgical solutions and greatly limits the use of this approach as a single modal-
ity. Future developments include further advancements in imaging methods, aug-
mented reality and simulation systems, and innovative tools and approach methods. 
These will certainly facilitate continuous improvement in efficacy and safety with 
regard to small lesions and an increased ability to effectively treat medium lesions. 
However, we fear that treating the majority of medium-to-large lesions will continue 
to necessitate multi-modal, fractionated, or novel approaches.
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7. Discussion and recommendations
The ARUBA trial, published in 2014, compared interventional therapy with 
medical management of unruptured brain AVMs. It was a broad trial involving 39 
active clinical sites in nine countries. The study recruited 223 patients during the 
period from April 2007 to April 2013. About 114 of the patients were assigned to 
interventional therapy and 109 to medical management. The conclusions were that 
the risk of death or stroke is significantly lower in the medical management group 
than in the interventional therapy group (hazard ratio 0.27). Naturally, the study 
elicited a plethora of reactions that we will not fully cover since they are outside the 
scope of this review. Some, that were relatively more supportive, identified ARUBA 
as the only randomized trial at that time (2010) with clear clinical outcomes com-
paring different interventional treatments for brain AVMs with conservative medi-
cal therapy [100]. More reactions were less supportive, criticizing the pragmatic 
design, the patients’ heterogeneity, the lack of standardization of the treatment 
arm, the choice of outcome measures, the short follow-up period, the small popula-
tion, and so forth [87, 101, 102]. The controversy also led the European societies 
dealing with the treatment of AVMs to conduct a consensus conference at the 
European level [104]. Among the statements made were two key points which we 
quote: “There are sufficient indications to treat unruptured AVMs Grade 1–2 SM” 
and “There may be indications for treating patients with higher SM grades, based 
on a case-to-case consensus decision of the experienced team.” One clear consensus 
emerges—further research is advocated to delineate the optimal management 
of unruptured AVMs, particularly those with SM grade≥3 [103]. Furthermore, 
judicious observation of the literature since ARUBA indicates that there may be a 
lacuna or at least weakness in interventional modalities when addressing high SM 
grade AVMs. This fact has not traversed the community unnoticed. All three main 
interventional modalities present a similar line—advancement in existing treatment 
paradigms, treatment planning, and intra-operative measures. However, to date, the 
core challenge persists. We feel that one possible cause is the limitations inherent in 
present approaches that lead to diminishing returns with every new improvement 
(necessitating ever-increasing technological and financial investments). The two 
leading avenues of interventional choice for medium-to-large lesions are currently 
multi-modal and staged treatment. When considering multi-modal treatment, we 
must take into account other factors besides medical outcomes. Multi-disciplinary 
AVM treatment suffers from a fundamental market/commercial flaw. Every manu-
facturer focuses on its core technologies (whether they are embolic agents, radiation 
therapy equipment, etc.), and these typically do not complement one another. 
This considerably impedes R&D of novel multi-modal techniques and protocols 
by leaving them in the hands of mostly research endeavors that lack the financial 
resources of commercial companies. Interestingly, this fact is clearly reflected in the 
literature. The number of papers we reviewed dealing with single modality treat-
ment is an order of magnitude larger (speaking cautiously…) than those adopting 
a multi-modal approach. This trend continues for the number of patients treated. 
To conclude, we fear that multi-modal treatment faces inherent financial and 
technical limitations that strongly impede its chances of reaching full potential and 
will continue to do so in the near future. Fractionated radiation and multi-session 
(staged) embolization also suffer similar logistic and economic flaws. It is very 
challenging to repeatedly admit patients to very complex and expensive procedures 
also requiring highly experienced medical experts who are typically in “short sup-
ply,” and advanced facilities, particularly in radiation treatment. Considering this 
state of affairs, we conclude that it could be advantageous to consider a treatment 
approach that has not been used to address AVM in the past—continuous mild 
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irradiation provided via an implantable active source. The use of such implants in 
Brachytherapy is very well established and dates back decades (if not a century). 
Much knowledge has been accumulated in the field (we will not review the subject 
due to lack of space). Such an implant has the potential to elicit a hyperproliferative 
effect facilitating lumen closure by thickening of the vascular wall by exploiting the 
“candy wrapper” or edge effect (see further data below).
First, let us attempt to convince the readers that this approach merits medical 
investigation. In Section 6.1, we explained that there are two major changes in tissue 
when exposed to radiation—degeneration and proliferation. Both changes are 
dose- and time-dependent. Therefore, there is room for adjusting and augmenting 
each by controlling radiation kinetics and spatial distribution patterns. Active stent 
studies show proliferation and restenosis reduction (typically in-stent) but also 
induction (typically at the stent edges). Albiero et al. implanted 122 32P radioactive 
β-emitting stents (activity levels of 0.75–12.0 μCi) in 91 lesions in 82 patients [105]. 
After 6-month follow-up, they found that intrastent restenosis was 0–16% (depend-
ing on implant activity; high activity stents showed no restenosis). However, they 
also found that restenosis at stent edges was 41–52% (maximal for the lowest activ-
ity stents!). They concluded that the use of active stents in patients with coronary 
artery disease is feasible and named this edge effect as the “candy wrapper.” They 
speculated that the effect was a result of low radiation at the stent edges combined 
with an aggressive approach to stenting (pre-dilatation with an oversized balloon). 
Shortly after, they also demonstrated that stents with higher initial activity levels 
of 12–21 μCi (54 lesions) reduced intrastent neointimal hyperplasia compared 
with stents of 3–12 μCi (42 lesions) [106]. However, they did not eliminate edge 
restenosis (38% for the lower activity stents were reduced just to 30% for the 
higher activity stents). Since they used a non-aggressive stent implantation strategy 
(pre-dilatation with a non-oversized balloon) in the second study, they also ruled 
out that the edge effect is attributable to the implantation procedure. Wardeh et al. 
implanted 31 stents in 26 patients [107]. They corroborated this deduction (also 
attributing the edge effect to low radiation levels) and concluded that the use of low 
activity radioactive stents is safe and feasible. Sianos et al. analyzed 175 human ves-
sels (131 were eventually eligible) treated according to the beta-radiation in Europe 
(BRIE) study protocol [108]. They wanted to evaluate the impact of Geographical 
Miss (GM—a situation in which the radiation source does not fully cover the injured 
vessel segment) on edge restenosis after intracoronary beta-radiation therapy. The 
injured edges of the effective irradiated segment (EIRS) constituted the GM edges. 
Restenosis was defined as diameter stenosis >50% at follow-up (6 months). They 
found GM affected 41.2% of the edges and significantly increased edge restenosis to 
16.3% compared with 4.3% in non-GM edges (for both proximal and distal edges). 
GM associated with stent injury increased edge restenosis more than that associated 
with balloon injury (from 3.6% with no GM to 18.75% compared with from 5.36 to 
10.71%, respectively). However, EIRS restenosis was similar between vessels with 
and without GM (24.3 and 21.6%, respectively), thus indicating a dominant effect 
for radiation fall origins. Van der Giessen et al. investigated the edge effect in the 
coronary arteries of Yucatan micropigs [109]. They fabricated half radioactive and 
half non-radioactive stents (n = 20, with 10 regular stent controls). Their design 
introduced a mid-stent radioactive dose falloff zone next to a non-radioactive 
stent-artery transition at one side and a radioactive stent-artery transition at the 
other side. They demonstrated a significant mid-stent stenosis at 4 weeks follow-
up. Two animals died suddenly because of coronary occlusion at this mid-zone at 
8 and 10 weeks. At 12 weeks, there was a significant neointimal thickening at the 
mid-stent dose-falloff zone of the half-radioactive stents but not at the stent-to-
artery transitions at both extremities. No mid-stent response was observed in the 
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non-radioactive stents. They concluded that the edge effect is associated with the 
combination of stent injury and radioactive dose falloff. Studies performed on 
both human subjects and animal models found a significant neointimal increase 
at low activity stents edges [110]. These findings seem clinically significant since 
low-dose-related neointimal hyperproliferation, when compared with conventional 
radiosurgery, does not appear to be associated with damage to the Tunica Adventitia 
or Vasa Vasorum, hyaline phenotypes, or any endothelial disfunction (degeneration 
traits). Desouky et al. recently reviewed the targeted and non-targeted effects of 
ionizing radiation [111]. They describe cell and tissue response to low-dose/dose 
rate ionizing radiation. Cells exposed to such radiation exhibit increased cellular 
communication and resistance to future irradiation. They conclude that exposure 
of human cells to low radiation induces molecular processes that are different 
from those induced by high dose radiation. Furthermore, the effects of ionizing 
radiation are not restricted to irradiated cells but also affect non-irradiated cells via 
mechanisms termed “Radiation Bystander Effects” and “Radioadaptive Response” 
[111]. This suggests that a low-dose/dose rate source can potentially affect a larger 
volume than that anticipated from direct energy absorbance evaluations based on 
our experience with high-energy treatments.
The edge effect has always been treated as an adverse phenomenon. However, in 
AVM treatment, the objective is precisely the opposite of most traditional vascular 
procedures—obliteration rather than revascularization. Here, we suggest that 
if exploited properly, this effect may prove highly beneficial. Let us explain its 
potential advantages:
• An implant can be introduced in a minimally invasive manner by an interven-
tional neuroradiologist alongside embolization or standalone. The expertise 
required for these procedures overlaps considerably.
• Gradual closure of the blood vessels will not elicit rapid hemodynamic irregu-
larities that are well known to induce adverse effects such as hemorrhage.
• A single implantation procedure yields short overall operative/hospitalization 
time with FT or staged embolization. No recurrent patient admittance also 
ensures adequate costs compared with staged interventional procedures (also 
considering hospitalization charges).
• The literature indicates that lumen occlusion in these settings requires months. 
This can possibly lead to a shorter overall treatment period compared with FT 
or staged embolization (that can take up to years) and thus reduce hemorrhage 
risks.
• Treatment time for SRS is typically up to ~2 h. For FT, let us multiply it by 
up to 5 which is a common session number—indicating ~10 h. Let us now 
assume that the continuous source is decaying over a period of just 3 months 
~3*30 day/month*24 h/day = 2160 h. This indicates that a dose rate more than 
a 1000 times smaller compared with that which is used in SRS or more than 
200 times smaller compared with FT could eventually provide the same overall 
absorbed energy. This is clearly not a sufficient medical proof since we know 
FT is less efficient than radiosurgery in obliteration rates and we certainly 
have no evidence of the effectiveness of such a source type and radiation levels 
in the AVM context. However, it does clearly indicate the potential for dose-
rate reduction. Many AREs that originally motivated FT could be inherently 
circumvented when mild constant radiation is employed instead of short-lived 
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high-intensity energy doses/rates. Mild radiation also ensures a much better 
contained isodose distribution compared with the target volume and thus 
affected brain volume (Figure 8).
• A mammalian cell cycle typically lasts around a day (~24 h). A treatment 
lasting up to 2 h will not overlap with each of the cell cycle stages. However, a 
continuous source will expose the lesion cells to radiation during each of their 
cell cycle stages. We know from cancer treatment experience that this can 
prove highly beneficial. No data is available to indicate this also applies in the 
case of AVM treatment. However, this is certainly a point to consider.
• There is a mature and experienced medical device/implant industry that can 
reasonably rapidly adjust to develop and fine-tune such implants to AVM clini-
cal requirements.
• Device/implant procedures are relatively easily attuned to qualify for reim-
bursement regulations, so insurance companies and medical centers can adopt 
the treatment modality.
• In contrast with embolic agents, a radiation source does not have to occupy 
each and every AVM blood vessel because it inherently supports a collateral 
effect. This leaves a very wide and flexible working range for the physicians 
regarding the final implantation position.
To conclude, if proven feasible, low-radiation implants could add several unique 
benefits to AVM treatment and we advocate studying their use.
Figure 8. 
Illustration of the conceptual differences between the presumed radiation traits required from a continuous 
source and those required from the current two predominant treatment modalities—radiosurgery and FT. Left: 
radiation dose/rate kinetics. Right: isodose map (the same dashing indicates equal radiation levels). The 
continuous source is constantly effective, thus necessitating significantly reduced doses/rates and facilitating a 
much better contained radiation distribution field, reduced affected brain volume, and potentially reduced 
AREs.
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